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Abstract
Background: In-stent restenosis occurs in 10–30% of patients following bare metal stent (BMS) implantation and
has various risk factors. Mannose-binding lectin (MBL) is known to have effect on the progression of atherosclerosis.
Single nucleotide polymorphisms (SNP) of the MBL2 gene intron 1 (codon 52, 54, 57) are known to modulate the
bioavailability of the MBL protein. Our aim was to identify the association of these polymorphisms of the MBL gene
in the occurrence of in-stent restenosis after coronary artery bare metal stent implantation.
Methods: In a non-randomized prospective study venous blood samples were collected after recoronarography
from 225 patients with prior BMS implantation. Patients were assigned to diffuse restenosis group and control
group based on the result of the coronarography. MBL genotypes were determined using quantitative real-time
PCR. Proportion of different genotypes was compared and adjusted with traditional risk factors using multivariate
logistic regression.
Results: Average follow-up time was 1.0 (+ − 1.4) year in the diffuse restenosis group (N = 117) and 2.7 (+ − 2.5)
years in the control group (N = 108). The age, gender distribution and risk status was not different between study
groups. Proportion of the MBL variant genotype was 26.8% (29 vs. 79 normal homozygous) in the control group
and 39.3% (46 vs. 71 normal homozygous) in the restenosis group (p = 0.04). In multivariate analysis the mutant
allele was an independent risk factor (OR = 1.96, p = 0.03) of in-stent restenosis.
Conclusions: MBL polymorphisms are associated with higher incidence of development of coronary in-stent
restenosis. The attenuated protein function in the mutant allelic genotype may represent the underlying
mechanism.
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Background
Coronary interventions revolutionised the treatment of
acute and stable forms of coronary artery disease (CAD)
[1]. However, after balloon angioplasty restenosis of the
target segment of the vessel occurs in 40–50% [2]. Cor-
onary stents were designed to lower the rate of early
restenosis. The most common complications of stent
implantation are stent thrombosis and in-stent resten-
osis (ISR). While stent thrombosis is known to be
associated with thrombocyte function, ISR is associated
with endothel proliferation. ISR still occurs in 10–30%
of the interventions with deployment of bare metal
stents (BMS), therefore it still forms a clinically import-
ant problem [3]. With the use of drug eluting stents
(DES) or other modern stents designed to lower the
ratio of endothel proliferation, restenosis ratio could be
further reduced. However, indication of these stents is
less wide and the cost of these stents is significantly
higher, therefore BMS’s are still widely used. Risk factors
for in-stent restenosis could be classified in two groups.
Procedural-dependent or local factors are: diameter of
vessel, length of lesion or stent, minimal lumen diameter
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before and after stenting, ostial lesions, stent fracture, total
occlusions [4]. The other group consists of patient-
dependent or general factors. Risk for restenosis is par-
ticularly high among patients with diabetes mellitus, this
may be associated with metabolic alterations that promote
endothelial dysfunction [5], accelerate intimal hyperpla-
sia [6], and increased platelet aggregability and thrombo-
genicity. There is evidence that gender itself (female)
predisposes to restenosis, and some patients may have a
genetically higher risk [7]. Genetic polymorphisms associ-
ated with high risk for restenosis include polymorphisms
in genes coding for angiotensin-converting enzyme inhibi-
tor [8, 9], glycoprotein receptor IIIa [10] and haptoglobin
[11]. On invasive coronarography in-stent restenosis can
be classified according to the Mehran’s classification to
focal (Mehran I) and diffuse (Mehran II-IV) groups [12].
The former type is determined by local and procedural
factors, while the latter shows a significant relationship
with general, patient-related factors [13].
Mannose-binding lectin
Mannose-binding lectin (MBL) is an acute phase protein
produced by the liver as part of the innate immune
system. It also has a direct opsonisation effect by binding
to cell-surface receptors on phagocytes. It is present in
the blood serum forming a complex with serine prote-
ases [14, 15]. According to the results of prior studies a
low level of MBL is related to the rapid progression of
atherosclerosis [16], severe coronary artery disease [18]
and/or increased carotid plaque formation and graft oc-
clusion after bypass surgery. Functioning alleles show an
association with the serum level of MBL protein.
Genetic background
MBL protein is encoded from the MBL2 gene on chromo-
some 10. Single nucleotide polymorphisms (SNP) in exon
1 concerning the promoter region of the MBL2 gene are
known to reduce the amount of functional MBL subunits
5- to 10-fold, resulting in lower serum levels of MBL: at
codon 52 (arginine to cysteine, allele D), codon 54 (glycine
to aspartic acid, allele B,) and codon 57 (glycine to glu-
tamic acid, allele C). These variant alleles are commonly
named as O, and the normal allele has been named A
[19]. Impaired production of MBL is associated with these
three SNP-s [20].
Based on these findings that indicate probable involve-
ment of the MBL system in the pathological processes
leading to restenosis, and the impaired MBL production
related to these SNP-s our study was performed to ana-
lyse the association of MBL2’s polymorphisms and the
development of coronary in-stent restenosis after bare
metal stent deployment.
Methods
Subjects, interventions and follow-up
In our non-randomized prospective study, we investi-
gated patients who had re-coronarography in the Heart
and Vascular Center, Semmelweis University between
2009 and 2011 due to symptoms of non-acute cardiac
event (stable, instable or effort angina pectoris) or acute
coronary syndrome. All the patients received BMS dur-
ing the first percutaneous coronary intervention (PCI),
we excluded patients from this study who received DES.
All patients received standard therapy according to the
actual guidelines. ISR were evaluated by experienced
clinicians according to Mehran’s classification.
The restenosis group included patients received BMS
during the first PCI and had significant diffuse ISR
(Mehran II-IV) at recoronarography. A total number of
117 patients (83 men (70.9%)) were included.
Control group (n = 108) formed by patients who
received BMS during the first PCI and had recoronaro-
graphy because of novel complaints, but developed no
or only focal restenosis (Mehran I) in the target bare
metal stent.
Biological samples and genotyping
Total genomic deoxyribonucleic acid (DNA) was
extracted from EDTA-anticoagulated blood samples
collected after the second coronarography using the
method of Miller et al. Determination of the alleles of
the MBL2 gene at codons 52 (D - rs5030737), 54 (B -
rs1800450), and 57 (C - rs1800451) were performed by
polymerase chain reaction using sequence-specific prim-
ing. The common designation for these variant alleles is
O, whereas the normal allele has been named A [19].
Statistical analyses
Data were collected in Microsoft Excel 2003 and were
analysed with SPSS 13.0 for Windows (SPSS, Chicago,
USA) software. Categorical variables were reported as
absolute numbers and percentages, and continuous vari-
ables as medians and interquartile ranges. We used the
t-test to compare continuous variables between groups,
whereas for continuous nonparametric variables we used
the Mann–Whitney U-test. Categorical values were
compared by using the chi-square test. Multivariate
logistic regression has been performed with adjustment
for generally known risk factors and MBL variant geno-
type (A/O +O/O) with in-stent restenosis as a dependent
variable, independent variables were entered into the
equation simultaneously. The genotype frequency was
tested for deviation from Hardy–Weinberg equilibrium by
using Pearson’s chi-square test. All analyses were
performed two-tailed, and p < 0.05 was considered as
significant.
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Results
Patient characteristics
The average follow-up time was 2.7+/−2.5 years in the
control group and 1.0+/−1.4 years in the restenosis group
(p < 0.0001). According to this diffuse restenosis occurred
and caused symptoms earlier while controls had a longer
asymptomatic period before re-coronarography was per-
formed. Clinical baseline characteristics of the 225 pa-
tients are described in Table 1, dividing study participants
in two groups. The mean age (control: 66.4 (+ − 10.8)
years vs. restenosis: 65.7 + −9.9 years; p = 0.632) and distri-
bution of genders (control: 76.9% male vs. restenosis
70.9% male; p = 0.314) did not differ significantly in the
two groups.
The presence of risk factors such as hypertension, dia-
betes, hyperlipidaemia, obesity, multivessel disease did
not differ significantly in the groups. About one-third of
patients had diabetes (78 patients, 34.7%), mostly type 2.
Most patients had hypertension and hyperlipidaemia,
only 6% were not treated for hypertension and 9% were
not on lipid-lowering therapy and had normal lipid
levels. Obesity (body mass index (BMI) >25) was present
in 74% of patients. Multiple vascular disease was
detected in 49 patients (24.1%) at the time of the recoro-
narography, 23 (11.3%) cases had the anamnesis of
stroke or TIA and 35 (17.2%) cases had peripheral artery
disease in the anamnesis. 11 patients had renal failure
and 6 patients had cardiogen shock.
Interventions
There was no significant difference in the indication of
stent implantation between the two groups: acute coronary
disease in 57% of the control group and 57.3% in the re-
stenosis group. Total number of deployed stents was sig-
nificantly higher in restenosis group 1.37 (+ − 0.54) vs 1.69
(1.04) (p = 0.005). There were only a few patients (n = 29,
13%) who had multiple branches stented for the first inter-
vention, 10 (9.4%) in the control group and 19 (16.2%) in
the restenosis group (p = 0.131).
Genotype distribution and statistical analysis
Allele frequencies were similar between genders (67.7/
31.1/1.2 in men and 67.2/35.6/1.7 in women, p = 0.778).
The genotype distribution did not deviate from Hardy–
Weinberg equilibrium (p = 0.08). Proportion of the MBL
variant genotype (A/O +O/O) was 26.8% (29 vs. 79 nor-
mal homozygous) in the control group and 39.3% (46 vs.
71 normal homozygous) in the restenosis group (OR:
1.784, p = 0.04) (Table 2).
Univariate analysis revealed that MBL variant genotype
(A/O +O/O) (OR: 1.784, p = 0.047) and total number of
implanted stents (OR: 0.519 , p = 0.034) influence the
development of in-stent restenosis. We performed multi-
variate adjustment for known risk factors (gender, age,
BMI, hypertension, dyslipidaemia, diabetes mellitus,
smoking, acute coronary disease and total number of im-
planted stents) and MBL variant genotype (A/O +O/O) as
covariates. The regression analysis revealed that MBL vari-
ant genotype (OR: 1.95, p = 0.03), BMI (OR: 1.08, p = 0.03)
and total number of implanted stents (OR: 1.64, p = 0.01)
are independently associated with development of in-stent
restenosis (Table 3).
Discussion
Mannose-binding lectin is an acute phase protein pro-
duced by the liver as part of the innate immune system.
In our non-randomized prospective study, multivariate
analysis revealed that the MBL variant genotype (A/O +
O/O) is independently associated with and has a signifi-
cant effect upon the development of in-stent restenosis.
After coronary artery stent implantation, patients are at
a higher risk of diffuse in-stent restenosis if they are
carrying variant MBL alleles (A/O or O/O) than those
homozygous for the normal MBL A/A genotype. The
link between polymorphisms and restenosis is that single
nucleotide polymorphisms (SNP) concerning the pro-
moter region of the MBL2 gene are known to influence
the bioavailability of MBL by resulting in a lower serum
concentration [21].
Clinical observations show that low serum levels of
MBL can predispose to several infections, especially
those involving the respiratory system and may play a
Table 1 Patient characteristics
Characteristics Control group
(n = 108)
Restenosis group
(n = 117)
p-value
Age (years) 66.4 (+−10.8) 65.7 (+−9.9) 0.632
Gender, male (%) 83 (76.9%) 83 (70.9%) 0.314
Anti-hypertensive therapy (%) 104 (96.3%) 108 (92.23%) 0.200
Lipid-lowering therapy (%) 98 (90.7%) 107 (91.5%) 0.851
Diabetes mellitus (%) 39 (36.1%) 39 (33.3%) 0.662
Obesity - BMI > 25 (%) 76 (70.4%) 91 (78.4%) 0.165
Smoking 32 (47.1%) 36 (52.9%) 0.927
Multi-vessel disease (%) 10 (9.4%) 19 (16.2%) 0.131
Acute coronary disease (%) 61 (57%) 67 (57.3%) 0.969
Follow up time (years) 2.73 (+−2.54) 1.03 (+−1.38) <0.001
Total number of stents 1.37 (+−0.54) 1.69 (1.04) 0.005
Table 2 Genotype distribution
MBL genotype Control
group
n = 108 (%)
Diffuse restenosis
group
n = 117 (%)
p-value
Normal (A/A carriers) 79 (73.1%) 71 (60.6%) 0.04
Variant (A/0 + 0/0 carriers) 29 (26.8%) 46 (39.3%)
A/A vs A/0 + 0/0, Khi-square
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role in certain autoimmune disorders [22, 23]. It has
been suggested by others that MBL deficiency also plays
a role in several non-infectious diseases such as systemic
lupus erythematosus [24], type 2 diabetes mellitus [25],
cystic fibrosis [26], rheumatoid arthritis [27] and Crohn’s
disease [28].
Previously it has been shown that MBL deficiency may
be associated with accelerated atherosclerosis [16, 17]
and also coronary plaque formation [29, 18]. Its associ-
ation with the progression of atherosclerosis can be ex-
plained in different ways. Several studies have
demonstrated the relationship between chronic Chla-
mydia pneumoniae (intracellular bacteria) infection and
coronary artery stenosis [30, 31]. Given that most people
are exposed to this infection during their lifetime, it is
feasible that the lack of MBL modifies the quality and/or
intensity of the immune reaction against Chlamydia
[29]. Higher rate of restenosis may be caused by the pro-
longation of the inflammatory response and the healing
process of the endothelium [32]. Furthermore, MBL has
an influence on the progression of atherosclerosis irre-
spective of neointima hyperplasia.
In contrast, Széplaki et al. found that a significant
increase in the frequency of MBL variant genotypes was
observed in patients not experiencing restenosis
compared with the patients with restenosis after carotid
endarterectomy [33]. The higher incidence of early
restenosis after carotid endarterectomy was associated
with elevated C3 level and carrying the wild type of
MBL2 allele [34].
Limitations
We presented a genetic association study in a relatively
small sample size, with considerably wide confidence in-
tervals for odds ratios, therefore a spurious association
cannot be fully ruled out. Further studies are needed and
sample size should be increased to confirm the results of
the present study. Plasma MBL levels could be deter-
mined for a better understanding how MBL polymor-
phisms affect restenosis after percutaneous coronary
interventions.
Conclusions
In our study, multivariate analysis revealed that MBL vari-
ant genotype (A/O +O/O) is independently associated
with and has a significant effect upon the development of
in-stent restenosis. According to our results and the
results of others, it is likely that the mechanisms leading
to restenosis are different in the carotid and coronary
arteries. The MBL genetic system may be a promoter or a
protector factor of the atherosclerosis depending on the
pathophysiological scenario within the vessel wall and that
it is a fine-tuned balance that determines whether comple-
ment is an advantage or disadvantage in cardiovascular
disease settings. In conclusion, our study shows that MBL
polymorphisms’ are associated with the development of
coronary in-stent restenosis. The attenuated protein func-
tion related to the mutant allelic genotype may represent
the underlying mechanism.
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